KRAS and non-small cell lung carcinoma: NSCLC patients with KRAS mutation have a notoriously poor prognosis.[6–8] Although target agents against KRAS G12C mutation, such as sotorasib, have been revealed promising efficacy, the unmet need of the treatment for other KRAS subtypes remained unresolved.[9] On the other hand, immune checkpoint inhibitor (ICI) may provide survival benefits for NSCLC patients harboring the KRAS mutation.[10,11] Factors such as the expression level of programmed death-ligand 1 (PD-L1) or different KRAS subtypes may predict the ICI treatment outcomes, but it remains unclear.[12]